40,639 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Erste Asset Management GmbH

Erste Asset Management GmbH bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 40,639 shares of the biopharmaceutical company’s stock, valued at approximately $42,480,000.

A number of other hedge funds also recently added to or reduced their stakes in REGN. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after buying an additional 96,266 shares during the last quarter. TD Asset Management Inc boosted its position in shares of Regeneron Pharmaceuticals by 30.4% in the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after buying an additional 82,034 shares in the last quarter. Icon Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Regeneron Pharmaceuticals by 86.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 144,865 shares of the biopharmaceutical company’s stock valued at $152,257,000 after acquiring an additional 67,235 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on REGN. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $750.22 on Friday. The company has a market cap of $82.44 billion, a PE ratio of 18.57, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $905.64 and a two-hundred day moving average price of $1,019.36. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.